US FDA consults on protecting subjects' rights in drug and medical device trials
This article was originally published in Clinica
Executive Summary
The US Food and Drug Administration is inviting feedback on a draft guideline that aims to help institutional review boards and others involved in drug and medical device trials determine whether the proposed research is reasonable and poses minimum risk to human subjects.